Clinical trials: Primary Brain Tumor
Brain Neoplasms, Malignant, Primary
Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System
The purpose of this crossover, single-dose, bioequivalence study is to compare the rate and extent of absorption of Temozolomide after the administration of the study product (Dralitem®, Monte Verde S.A.) and the reference…
- Trial name
- NCT02343081
- Testing
- Temozolomide
- Where
- 2 sites in Argentina
- Volunteers
- 24 people
- Sponsor
- Monte Verde SA
Protein Kinase Inhibitors, Other Protocol Specified Criteria
Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
An open, non-randomized, multicenter, single-arm dose-escalation design, phase 1 trial to study the safety, tolerability, pharmacokinetics and efficacy of JYP0322 in patients with ROS1+ locally advanced/metastatic solid tumors .
- Conditions
- Protein Kinase Inhibitors, Other Protocol Specified Criteria, Lung Neoplasms, Brain Neoplasms
- Trial name
- JYP0322 (NCT06128148)
- Testing
- JYP0322 50 mg qd, JYP0322 100 mg qd, JYP0322 200 mg qd
- Where
- China
- Volunteers
- 101 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Central Nervous System Neoplasms, Glioblastoma
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting…
- Conditions
- Central Nervous System Neoplasms, Glioblastoma, Gliosarcoma, Adult, Anaplastic Oligodendroglioma
- Trial name
- NCT04541082
- Testing
- ONC206
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Jazz Pharmaceuticals
Advanced Cancer
Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer"
DM-CHOC-PEN is a polychlorinated pyridine cholesteryl carbonate that has demonstrated antineoplastic activities in human xenograft intracerebrally implanted tumor mouse models, acceptable preclinical toxicities in mouse, rat and…
- Trial name
- DM-CHOC-PEN (NCT01976910)
- Testing
- DM-CHOC-PEN
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- DEKK-TEC, Inc.
Brain Tumor, Primary
The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment
An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for refractory primary brain tumors with BRAF mutation
- Trial name
- NCT05092802
- Testing
- HLX208
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Henlius Biotech
Advanced Cancer, Brain Involvement
Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer
DM-CHOC-PEN is a polychlorinated pyridine cholesteryl carbonate that has demonstrated antineoplastic activities in human xenograft intracerebrally implanted tumor mouse models, acceptable preclinical toxicities in mouse, rat and…
- Trial name
- DM-CHOC-PEN (NCT01048008)
- Testing
- DM-CHOC-PEN
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- DEKK-TEC, Inc.
Primary Brain Tumor
Laser Ablation in Stereotactic Neurosurgery (LAISE): NeuroBlate® Retrospective Registry
The NeuroBlate® System (NBS), is a minimally invasive robotic laser thermotherapy tool. It employs a pulsed surgical laser to deliver targeted energy to abnormal brain tissue caused by tumors and lesions.
- Trial name
- NCT02389855
- Testing
- NeuroBlate® System Therapy
- Where
- 9 sites in United States
- Volunteers
- 144 people
- Sponsor
- Monteris Medical
Glioblastoma Multiforme, Glioblastoma
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, GBM, Grade IV Astrocytoma
- Trial name
- GBM (NCT00045968)
- Testing
- Dendritic cell immunotherapy
- Where
- 86 sites in United States, Canada and 2 more
- Volunteers
- 348 people
- Sponsor
- Northwest Biotherapeutics
Brain Tumor, Glioma, Malignant
Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
Pear Bio has developed a 3D microtumor assay and computer vision pipeline through which the response of an individual patient's tumor to different anti-cancer regimens can be tested simultaneously ex vivo.
- Conditions
- Brain Tumor, Glioma, Malignant, Ependymoma, Oligodendroglioma
- Trial name
- PEAR-GLIO (NCT06038760)
- Testing
- Resection
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Ourotech, Inc.
Central Nervous System Tumors
Study of BLZ-100 in Pediatric Subjects With CNS Tumors
Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed.
- Trial name
- NCT02462629
- Testing
- BLZ-100
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Blaze Bioscience Inc.
Brain Neoplasms, Brain Tumor
MR Guided Laser Interstitial Thermal Therapy for the "Minimal Invasive" Treatment of Brain Metastasis and Primary Brain Tumors
The purpose of this study is to determine if the stereotactic, MR guided, laser interstitial thermal therapy treatment technique can be safety and efficiently used for human brain metastasis and primary brain tumors.
- Conditions
- Brain Neoplasms, Brain Tumor, Brain Cancer, Recurrent Brain Tumor
- Trial name
- NCT00392119
- Testing
- MR-guided Laser Interstitial Thermal Therapy System
- Where
- France
- Volunteers
- 18 people
- Sponsor
- BioTex, Inc.
Brain and Central Nervous System Tumors
Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery
RATIONALE: Biological therapies, such as lymphokine-activated killer cells, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00814593
- Testing
- lymphokine-activated killer cells, polifeprosan 20 with carmustine implant
- Where
- United States
- Sponsor
- Lisata Therapeutics, Inc.
Metastatic Brain Tumor, Primary Brain Tumor
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
The NeuroBlate® System (NBS) is a minimally invasive robotic laser thermotherapy tool that is being manufactured by Monteris Medical.
- Conditions
- Metastatic Brain Tumor, Primary Brain Tumor, Epileptic/Seizure Foci, Movement Disorders
- Trial name
- LAANTERN (NCT02392078)
- Testing
- NeuroBlate System
- Where
- 26 sites in United States
- Volunteers
- 1,153 people
- Sponsor
- Monteris Medical
Brain Neoplasms, Malignant Neoplasms, Brain
Study of Karenitecin (BNP1350) in Patients With Brain Tumors
The purpose of this study is to evaluate safety and efficacy ofKarenitecin (BNP1350) as a treatment of adults with brain tumors.
- Conditions
- Brain Neoplasms, Malignant Neoplasms, Brain, Brain Tumors
- Trial name
- NCT00062478
- Testing
- Karenitecin (BNP1350)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- BioNumerik Pharmaceuticals, Inc.
Advanced Solid Tumors
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
The purpose of the study is to test how well patients with advanced solid tumors respond to treatment with elimusertib (BAY1895344) in combination with pembrolizumab.
- Trial name
- NCT04095273
- Testing
- Elimusertib (BAY1895344), Pembrolizumab (Keytruda®)
- Where
- 16 sites in United States, Germany and 3 more
- Volunteers
- 56 people
- Sponsor
- Bayer
Tuberous Sclerosis Complex, Epilepsy
Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1)
This Phase 2, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, and efficacy of oral AV078 in participants with refractory epilepsy due to tuberous sclerosis complex (TSC).
- Trial name
- RESTOR-1 (NCT07680322)
- Testing
- AV078
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- Aeovian Pharmaceuticals, Inc.
Primary Brain Tumor
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
The purpose of this study is to demonstrate non-inferiority of Dotarem®-enhanced MRI as compared to Gadovist®/ Gadavist®-enhanced MRI in the diagnosis of brain tumors in terms of overall lesion visualization and characterization…
- Trial name
- REMIND (NCT02034708)
- Testing
- Dotarem®, Gadovist®/Gadavist®
- Where
- 32 sites in United States, Colombia and 2 more
- Volunteers
- 279 people
- Sponsor
- Guerbet
Dravet Syndrome, Lennox Gastaut Syndrome
Intermediate-Size Expanded Access Protocol (EAP) for LP352
This is an intermediate-size expanded access program (EAP) study. The purpose of this EAP is to provide continued access to LP352, an investigational drug product being investigated in participants with DEEs.
- Conditions
- Dravet Syndrome, Lennox Gastaut Syndrome, Developmental and Epileptic Encephalopathies
- Trial name
- NCT06149663
- Testing
- LP352
- Where
- 22 sites in United States, Australia
- Sponsor
- Longboard Pharmaceuticals
Malignant Melanoma, Carcinoma, Non-Small-Cell Lung
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
First-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF V600-mutated advanced solid tumor malignancies with…
- Conditions
- Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary, Brain Neoplasms
- Trial name
- NCT04543188
- Testing
- PF-07284890, Binimetinib, Midazolam
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 65 people
- Sponsor
- Pfizer
Lennox Gastaut Syndrome, Dravet Syndrome
Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY
This is a prospective, observational study on approximately 70-100 Real World participants affected by LGS, DS, or TSC treated with Epidyolex® as prescribed in the summary of product characteristics.
- Conditions
- Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
- Trial name
- EpiTALY (NCT05485831)
- Testing
- Epidiolex 100 mg/mL Oral Solution
- Where
- 18 sites in Italy
- Volunteers
- 111 people
- Sponsor
- Jazz Pharmaceuticals